%PDF-1.4
%
51 0 obj
<>
endobj
48 0 obj
<>
endobj
113 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-07-08T18:50:34Z
2024-03-29T04:59:30-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T04:59:30-07:00
application/pdf
Heather
2002-299.aug
uuid:03704887-1dd2-11b2-0a00-260927bd7700
uuid:03704889-1dd2-11b2-0a00-900000000000
endstream
endobj
37 0 obj
<>
endobj
38 0 obj
<>
endobj
52 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 19 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 23 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
16 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 31 0 R/Type/Page>>
endobj
139 0 obj
[143 0 R]
endobj
140 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 73.2 714.5293 Tm
(first cycle with recombinant interferon [letter]. It J Gastroenterol)Tj
0 -1.25 TD
(Hepatol 1998;30:234-5.)Tj
-1.95 -1.25 Td
[(28.)-700.1 (Simon DM, Gordon SC, Kaplan MM, et al. )17.7 (T)35 (reatment of chronic)]TJ
1.95 -1.25 Td
[(hepatitis C with interferon alfa-n3: a multicenter)39.7 (, randomized, )]TJ
T*
(open-label trial. Hepatology 1997;25:445-8.)Tj
-1.95 -1.25 Td
[(29.)-700.1 (Cacopardo B, Benanti F)79.7 (, Brancati G, Romano F)79.7 (, Nunnari )54.8 (A.)]TJ
1.95 -1.25 Td
(Leukocyte interferon-alpha retreatment for chronic hepatitis C)Tj
T*
[(patients previously intolerant to other interferons. J )17.7 (V)59.8 (iral Hepatol)]TJ
0 Tc 0 Tw T*
(1998;5:333-9.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(30.)-700.1 (Mazzaro C, Colle R, Baracetti S, Nascimben F)79.7 (, Zorat F)79.7 (, Pozzato G.)]TJ
1.95 -1.25 Td
[(Ef)17.7 (fectiveness of leukocyte interferon in patients af)17.7 (fected by )]TJ
T*
[(HCV)91.7 (-positive mixed cryoglobulinemia resistant to recombinant)]TJ
T*
(alpha-interferon. Clin Exp Rheumatol 2002;20:17-24.)Tj
-1.95 -1.25 Td
[(31.)-700.1 (Andreone P)110.7 (, Gramenzi )54.8 (AG, Cursaro C, et al. Interferon plus)]TJ
1.95 -1.25 Td
(ribavirin in chronic hepatitis C resistant to previous interferon)Tj
T*
(course: results of a randomised multicenter trial. J Hepatol)Tj
0 Tc 0 Tw T*
(1999;30:788-93.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(32.)-700.1 (T)69.9 (euber G, Ber)17.7 (g )17.7 (T)74 (, Hof)17.7 (fman RM, et al. Retreatment with )]TJ
1.95 -1.25 Td
(interferon-alpha and ribavirin in primary interferon non-responders)Tj
T*
(with chronic hepatitis C. Digestion 2000;61:90-7.)Tj
-1.95 -1.25 Td
[(33.)-700.1 (Min )54.8 (AD, Jones JL, Esposito S, et al. Ef)17.7 (ficacy of high-dose)]TJ
1.95 -1.25 Td
(interferon in combination with ribavirin in patients with chronic)Tj
T*
[(hepatitis C resistant to interferon alone. )54.8 (Am J Gastroenterol)]TJ
0 Tc 0 Tw T*
[(2001;96:1)36.9 (143-9.)]TJ
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(34.)-700.1 (Bresci G, Parisi G, Bertoni M, Scatena F)79.7 (, Capria )54.8 (A. Interferon plus)]TJ
1.95 -1.25 Td
(ribavirin in chronic hepatitis C non-responders to recombinant )Tj
T*
[(alpha-interferon. J )17.7 (V)59.8 (iral Hepat 2000;7:75-8.)]TJ
-1.95 -1.25 Td
[(35.)-700.1 (T)69.9 (euber G, Ber)17.7 (g )17.7 (T)74 (, Hof)17.7 (fmann RM, et al. Retreatment with )]TJ
1.95 -1.25 Td
(interferon-alpha and ribavirin in primary interferon-alpha )Tj
T*
(non-responders with chronic hepatitis C. Digestion 2000;61:90-7.)Tj
-1.95 -1.25 Td
[(36.)-700.1 (Salmeron J, Ruiz-Extremera )54.8 (A, )17.7 (T)69.9 (orres C, et al. Interferon versus)]TJ
1.95 -1.25 Td
(ribavirin plus interferon in chronic hepatitis C previously resistant)Tj
T*
(to interferon: a randomized trial. Liver 1999;19:275-80.)Tj
-1.95 -1.25 Td
[(37.)-700.1 (Zuckerman E, Keren D, Slobodin G, et al. )17.7 (T)35 (reatment of refractory)64.9 (,)]TJ
1.95 -1.25 Td
(symptomatic, hepatitis C virus related mixed cryoglobulinemia with)Tj
T*
(ribavirin and interferon-)Tj
/T1_1 1 Tf
0 Tc 0 Tw [0.2 (\002)]TJ
/T1_0 1 Tf
-0.00011 Tc 0.0251 Tw [0.1 (. J Rheumatol 2000;27:2172-8.)]TJ
-1.95 -1.25 Td
[(38.)-700.1 (Garini G, )54.8 (Allegri L, Carnevali L, Catellani )17.7 (W)91.8 (, Manganelli P)110.7 (,)-0.1 ( Buzio)]TJ
1.95 -1.25 Td
(C. Interferon-alpha in combination with ribavirin as initial treatment)Tj
T*
(for hepatitis C virus-associated cryoglobulinemic )Tj
T*
[(membranoproliferative glomerulonephritis. )54.8 (Am J Kidney Dis)]TJ
0 Tc 0 Tw T*
(2001;38:35-9.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(39.)-700.1 (Calleja JK, )54.8 (Albillos )54.8 (A, Moreno-Otero R, et al. Sustained response to)]TJ
1.95 -1.25 Td
(interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C)Tj
T*
[(virus-associated symptomatic mixed cryoglobulinemia. )54.8 (Aliment)]TJ
0.00729 Tw T*
[(Pharmacol Ther )-17.7 (1999;13:1)36.8 (179-86.)]TJ
0.02499 Tw -1.95 -1.25 Td
[(40.)-700.1 (Monteverde )54.8 (A, Ballare M, Beroncelli MC, et al:)]TJ
1.95 -1.25 Td
[(L)55 (ymphoproliferation in type II mixed cryoglobulinemia. Clin Exp)]TJ
T*
(Rheumatol 1995;13 Suppl 13:141-7.)Tj
-1.95 -1.25 Td
[(41.)-700.1 (Bedossa P)110.7 (, Poynard )17.7 (T)74 (.)-0.1 ( )54.8 (An algorithm for the grading of activity in)]TJ
1.95 -1.25 Td
(chronic hepatitis C. Hepatology 1996;24:289-93.)Tj
-1.95 -1.25 Td
[(42.)-700.1 (Kaneko S, Unoura M, Kobayashi K, Kuno K, Murakami S, Hattori)]TJ
1.95 -1.25 Td
[(N. Detection of serum hepatitis C virus RNA)-220.2 ([letter]. Lancet)]TJ
0 Tc 0 Tw T*
(1990;335:976.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(43.)-700.1 (Okamoto H, Sugiyama )36.8 (Y)128.9 (, Okada S, et al. )17.7 (T)69.9 (yping hepatitis C virus)]TJ
1.95 -1.25 Td
(by polymerase chain reaction with type-specific primers:)Tj
T*
(application to clinical surveys and tracing infectious sources. J Gen)Tj
T*
[(V)59.8 (irol 1992;73:673-9.)]TJ
-1.95 -1.25 Td
[(44.)-700.1 (Chomczynski P)110.7 (, Sacchi N. Single-step method of RNA)-220.2 (isolation by)]TJ
1.95 -1.25 Td
[(acid guanidinium thiocyanate-phenol-chloroform extraction. )54.8 (Anal)]TJ
T*
(Biochem 1987;162:156-9.)Tj
-1.95 -1.25 Td
[(45.)-700.1 (Efremov DG, Batista FD, Burrone OR. Molecular analysis of IgE)]TJ
1.95 -1.25 Td
(heavy chain transcripts expressed in vivo by peripheral blood)Tj
T*
(lymphocytes from normal and atopic individuals. J Immunol)Tj
0 Tc 0 Tw T*
(1993;151:2195-207.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(46.)-700.1 (Franzin F)79.7 (, Efremov DG, Pozzato G, )17.7 (T)35 (ulissi P)110.7 (, Batista F)79.7 (, Burrone O.)]TJ
34.95 80 Td
[(Clonal B-cell expansions in peripheral blood of HCV)91.7 (-infected)]TJ
T*
(patients. Br J Haematol 1995;90:548-52.)Tj
-1.95 -1.25 Td
[(47.)-700.1 (Zorat F)79.7 (, Mazzoran L, Gregorutti M, Baracetti S, Nascimben F)79.7 (,)]TJ
1.95 -1.25 Td
(Pozzato G. Retreatment with interferon plus ribavirin in patients)Tj
T*
[(af)17.7 (fected by chronic hepatitis C [abstract]. J Hepatol 1999;30:244.)]TJ
-1.95 -1.25 Td
[(48.)-700.1 (Baracetti S, Colle R, Gregorutti M, et al. Randomized trial of )]TJ
1.95 -1.25 Td
[(combination therapy in relapser or non-responder HCV)-257.3 (patients)]TJ
T*
([abstract]. J Hepatol 2000;32:107.)Tj
-1.95 -1.25 Td
[(49.)-700.1 (Norusis MJ. )54.8 (Advanced statistics. SPSS/PC. Chicago: SPSS Inc.;)]TJ
0 Tc 0 Tw 1.95 -1.25 Td
(1986.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.225 Td
[(50.)-700.1 (Davis GL, Esteban-Mur R, Rustgi )17.7 (V)128.9 (, et al. Interferon alfa-2b alone)]TJ
1.95 -1.225 Td
(or in combination with ribavirin for the treatment of relapse of)Tj
0 -1.225 TD
(chronic hepatitis C. N Engl J Med 1998;339:1493-9.)Tj
-1.95 -1.225 Td
[(51.)-700.1 (Reichard O, Norkrans G, Fryden )54.8 (A, Braconier JH, Sonnerbor)17.7 (g )54.8 (A,)]TJ
1.95 -1.225 Td
[(W)79.9 (eiland O. Randomised, double-blind, placebo-controlled trial of)]TJ
T*
(interferon alpha-2b with and without ribavirin for chronic hepatitis)Tj
T*
(C. Lancet 1998;351:83-7.)Tj
-1.95 -1.2 Td
[(52.)-700.1 (Brillanti S, Garson J, Foli M, et al. )54.8 (A)-220.1 (pilot study of combination)]TJ
1.95 -1.2 Td
(therapy with ribavirin plus interferon alfa for interferon alfa-)Tj
0 -1.2 TD
(resistant chronic hepatitis C. Gastroenterology 1994;107:812-7.)Tj
-1.95 -1.2 Td
[(53.)-700.1 (Kakumu S, )36.8 (Y)99.8 (oshika K, )17.7 (T)69.9 (anaka K, et al. Long-term carriage of)]TJ
1.95 -1.2 Td
(hepatitis C virus with normal aminotransferase after interferon in)Tj
T*
[(patients with chronic hepatitis C. J Med )17.7 (V)59.8 (irol 1993;41:65-70.)]TJ
-1.95 -1.2 Td
[(54.)-700.1 (Colantoni )54.8 (A, De Maria N, Idilman R, )17.7 (V)110.8 (an )17.7 (Thiel DH. Polymerase)]TJ
1.95 -1.2 Td
[(chain reaction for the detection of HCV)91.7 (-RNA: cryoglobulinemia as)]TJ
T*
(a cause of false negative results. It J Hepatol Gastroenterol)Tj
0 Tc 0 Tw T*
(1997;29:273-4.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.2 Td
[(55.)-700.1 (Bichard P)110.7 (,)-0.1 ( Ounanian )54.8 (A, Girard M, Baccard C, Rolachon )54.8 (A,)]TJ
1.95 -1.2 Td
[(Renversez JC. High prevalence of hepatitis C virus RNA)-220.2 (in the)]TJ
T*
(supernatant and in the cryoprecipitate of patients with essential and)Tj
-0.0051 Tc T*
(secondary type II mixed cryoglobulinemia. J Hepatol 1994;21:58-63.)Tj
-0.00011 Tc -1.95 -1.2 Td
[(56.)-700.1 (Mazzaro C, Panarello M, Carniello S, et al. Interferon versus)]TJ
1.95 -1.2 Td
[(steroids in patients af)17.7 (fected by HCV)91.7 (-associated cryoglobulinemic )]TJ
T*
(glomerulonephritis. Dig Liver Dis 2000;32:708-15.)Tj
-1.95 -1.2 Td
[(57.)-700.1 (Mazzaro C, Carniello S, Doretto P)110.7 (, et al. Interferon therapy in )]TJ
1.95 -1.2 Td
[(HCV)91.7 (-positive mixed cryoglobulinemia: viral and host factors)]TJ
T*
[(contributing to ef)17.7 (ficacy of the therapy)64.8 (. It J Gastroenterol Hepatol)]TJ
0 Tc 0 Tw T*
(1997;29:343-7.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.2 Td
[(58.)-700.1 (Rasul I, Shepherd F)73.9 (A, Kamel-Reid S, Krajden M, Pantalony D,)]TJ
1.95 -1.2 Td
[(Heathcote EJ. Detection of occult low-grade B-cell non-Hodgkin\325)54.8 (s)]TJ
T*
(lymphoma in patients with chronic hepatitis C infection and mixed)Tj
T*
(cryoglobulinemia. Hepatology 1999;29:543-7.)Tj
-1.95 -1.2 Td
[(59.)-700.1 (Zignego )54.8 (AL, Giannelli F)79.7 (, Marrocchi ME, et al. )17.7 (T\(14;18\))]TJ
1.95 -1.2 Td
(translocation in chronic hepatitis C virus infection. Hepatology)Tj
0 Tc 0 Tw T*
(2000;31:474-9.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.2 Td
[(60.)-700.1 (Mazzaro C, Franzin F)79.7 (,)-0.1 ( )17.7 (T)35 (ulissi P)110.7 (, et al. Regression of monoclonal )]TJ
1.95 -1.2 Td
[(B-cell expansion in patients af)17.7 (fected by mixed cryoglobulinemia)]TJ
T*
[(responsive to alpha-interferon therapy)64.8 (. Cancer 1996:77:2604-13.)]TJ
-1.95 -1.2 Td
[(61.)-700.1 (Zuckerman E, Zuckerman )17.7 (T)74 (, Sahar D, et al. )17.7 (The ef)17.7 (fect of antiviral)]TJ
1.95 -1.2 Td
(therapy on t\(14;18\) translocation and immunoglobulin gene)Tj
T*
(rearrangement in patients with chronic hepatitis C virus infection.)Tj
0 Tc T*
(Blood 2001;97:1555-9.)Tj
-0.00011 Tc -1.95 -1.2 Td
[(62.)-700.1 (Casato M, Mecucci C, )54.8 (Agnello )17.7 (V)128.9 (, et al. Regression of )]TJ
1.95 -1.2 Td
(lymphoproliferative disorder after treatment for hepatitis C virus)Tj
T*
(infection in a patient with partial trisomy 3, Bcl-2 overexpression,)Tj
T*
(and type II cryoglobulinemia. Blood 2002;99:2259-61.)Tj
-1.95 -1.225 Td
[(63.)-700.1 (Donada C, Crucitti )54.8 (A, Donadon )17.7 (V)128.9 (, Chemello L, )54.8 (Alberti )54.8 (A.)]TJ
1.95 -1.225 Td
(Interferon and ribavirin combination therapy in patients with)Tj
0 -1.225 TD
(chronic hepatitis C and mixed cryoglobulinemia [letter]. Blood)Tj
0 Tc 0 Tw T*
(1998;92:2983-4.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.225 Td
[(64.)-700.1 (Glue P)110.8 (, Rouzier)19.7 (-Panis R, Raf)17.7 (fael C, et al. )54.8 (A)-220.1 (dose-ranging study of)]TJ
1.95 -1.225 Td
(pegylated interferon alfa-2b and ribavirin in chronic hepatitis C.)Tj
T*
(Hepatology 2000;32:647-53.)Tj
-1.95 -1.25 Td
[(65.)-700.1 (Lindsay KL, )17.7 (T)35 (repo C, Heintges )17.7 (T)74 (, et al. )54.8 (A)-220.1 (randomized, double-blind)]TJ
1.95 -1.25 Td
(trial comparing pegylated interferon alfa-2b to interferon alfa-2b as)Tj
0 -1.25 TD
(initial treatment for chronic hepatitis C. Hepatology 2001;)Tj
0 Tc 0 Tw T*
(34:395-403.)Tj
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw -35.3375 -4.6182 Td
[(Mazzar)36.8 (o, et al: Therapy in cryoglobulinemia)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1781)Tj
ET
0 0 0 1 K
55 54 m
559 54 l
S
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
31 0 obj
<>stream
8;Z\6#u9PH%.sQakjPSqWPdQ[UaHSPOK\l3iV4gfb@LV*TD^O'aS>OqkMJ8co;t$o
rG_R[0u_#Yo2imUn,6!/f#0KjLZ?Y>(HqnH`O`PXrWc,oO(hhib'8(ocIj#S<0nI54E_,)(33@iX
'C3[*\&9R.#(464XcCQ.g,WeISZ]+Sg?kIHTt#q)[L84$p!/og2\,3TBVnO(M)C
4r-Yql@k-mk4uUf=H6@1??\u_p'WX:%.YA:Eo^srVmAGFkSdph0Zh2Y\:j/P7kp_(
Ip^e3#a1(F^iS58E8')&-NM.9(Y`&7_J\/((@%#rBX:3l@3:K_e_sUU]#M(^q%$@3
P1c%ng$KV^:^Fn`rZuOP9U%75c)#Cr2(ZJ+
bAO"Ik4D7IN9,hjREd^*W3atE`d".d]/itDaVZq+N[umCPW[Ec:"qp6l>Yu.12)hS
%$/:L?-UnV^e%:F6:pRApGsAGLSEh*?_Xc;pR!N2M1>ZeDdK
;1E:Ma.+3MD*k%4^GiH;3Gk[#L#EFhDQGmp8k@:_6Rp25Q8Nqn8\QlQT-24X'>i0V
;c)'_aYm$!ZtjV;o;m$?)qnC"iJ-J[[Cu.fcZ[NDh1aBSkDeP!X)p\"Rs"nsXL*_]
$Etg_)lY):;V^]9q8leDZZR\+bt74i:$Y;%].F>3nQgal5gta9U9`2.)\$ONbp@3S
2`>.E6#+Wg>pRD)mDlEj+='saVcXWl%%ul=T.l]l(P,ul'_2lB9HcIXrI.=5:o8=,
7uH`7He$scjV\s2ZO>_5Xb~>
endstream
endobj
35 0 obj
[/Indexed/DeviceRGB 255 34 0 R]
endobj
34 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
59 0 obj
<>
endobj
66 0 obj
<>
endobj
55 0 obj
<>
endobj
98 0 obj
<>
endobj
118 0 obj
<>
endobj
54 0 obj
<>
endobj
90 0 obj
<>stream
HUiPSY~/<#C ZVݴD$,&%,b `*...]8ctSըKWO35gT}u{:ߩ1
ៅE̋d# ikXz,C3|ts$9:h%J}#}_?#ǸGd.T]Ak%
89E{f%ǥ$I٪E2&"cD)&EIBYƼ1RL$ͱgÖeL#&${&R!+2Ep&!#iDʈ}D8I d~P_1G0!-"6Lb9r1,Ìv
BkVbQX*^Csb9lj6CC/7{륂#S02elꜩi=F;M_3|Etwzkkz-wkܟ:|R =^lzC&ȅ>qܕ[OӛU)ԊDVOOJu*/em,.)i9j5lD-0BrJ0i[LCS\Ȱ"˂<MǦ/ܳLJBvZsWk.}=}[p pt s鑫Nu1(5GY{7Vi4u랴3_n sN@e[@FϫlT77hJ_Ljm)
8j%ƗwU˿aÿJnrN.@Gks
3oGde?}(+Uenkm[DoF&tC ,8c"ٟSm}-ec9:r{(IPVP(\Jc3Rb3yS^TZSsN4W?ou